Sep. 24, 2009 (PR Newswire) -- SAN DIEGO, Calif., INDIANAPOLIS, Ind., and CAMBRIDGE, Mass., Sept. 24, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) will unveil data from more than 20 studies at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, taking place from Sept. 29 to Oct. 2. The companies will present the latest research findings on BYETTA(R) (exenatide) injection and exenatide once weekly. The EASD annual meeting, which brings together more than 14,000 delegates, is the most important platform in Europe for professional exchange in the diabetes field.
"The presentations at EASD continue to reinforce the efficacy and safety of BYETTA and the promise of exenatide once weekly as a potential new treatment option for patients with type 2 diabetes," stated Orville G. Kolterman, M.D., senior vice president of research and development, Amylin Pharmaceuticals. "EASD is a venue where researchers and clinical practitioners from around the world gather to discuss new developments in diabetes care. We look forward to participating in this exchange of ideas by presenting compelling data on the exenatide molecule."
Key exenatide abstracts for EASD 2009 include:
Clinical Trial Data
-- Poster: Presentation #729, Sept. 30, 1:45-2:45 p.m. CEST "Effects
of Exenatide plus Rosiglitazone on Measures of Beta Cell Function and
Insulin Sensitivity in Subjects with Type 2 Diabetes Previously Treated
With Metformin" will be presented by Leonard Glass, M.D.
-- Poster: Presentation #730, Sept. 30, 1:45-2:45 p.m. CEST "Exenatide
Once Weekly Treatment Elicits Sustained Glycaemic Control and Weight
Loss Over 2 Years" will be presented by Michael Trautmann, M.D.
-- Poster: Presentation #739, Oct. 1, 12:45-1:45 p.m. CEST
"DURATION-2: Exenatide Once Weekly Demonstrated Superior Glycemic
Control and Weight Reduction Compared to Sitagliptin or Pioglitazone
After 26 Weeks of Treatment" will be presented by Carol Wysham,
M.D.
-- Poster: Presentation #795, Oct. 1, 12:45-1:45 p.m. CEST "Changes in
Adipokines in Type 2 Diabetic Patients Treated with Exenatide versus
Glimepiride on Metformin Background - Results of a Prospective,
Randomized Controlled Study Over 9 Months" will be presented by
Baptist Gallwitz, M.D.
Safety Assessments
-- Oral: Presentation #6, Sept. 30, 12:15-12:30 p.m. CEST "Incidence
of Acute Pancreatitis in Exenatide Initiators Compared to Other
Antidiabetic Drug Initiators: A Retrospective, Cohort Study" will
be presented by Gary Bloomgren, M.D.
-- Poster: Presentation #758, Oct. 2, 12:45-1:45 p.m. CEST "Exenatide
Once Weekly Improved Cardiometabolic Risk Factors in Subjects with Type
2 Diabetes During One Year of Treatment" will be presented by
Richard Bergenstal, M.D.
-- Poster: Presentation #759, Oct. 2, 12:45-1:45 p.m. CEST
"Cardiovascular Safety of Exenatide BID: An Integrated-Analysis
from Long-Term Controlled Clinical Trials in Subjects with Type 2
Diabetes" will be presented by Larry Shen, Ph.D.
-- Poster: Presentation #768, Oct. 2, 1:45-2:45 p.m. CEST "Safety and
Tolerability of Exenatide BID in Patients With Type 2 Diabetes:
Integrated Analysis of 3854 Patients From 11 Comparator Controlled
Clinical Trials" will be presented by Matthew Wintle, M.D.
Patient-Reported Outcomes
-- Poster: Abstract Presentation #745, Oct. 1, 12:45-1:45 p.m.
